Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2015 08:00 ET | Source: Receptos, Inc.

Receptos to Present at Jefferies 2015 Global Healthcare Conference

SAN DIEGO, May 28, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
May 15, 2015 08:00 ET | Source: Receptos, Inc.

Receptos Announces Oral Plenary Presentation of TOUCHSTONE Phase 2 Induction Data at Digestive Disease Week 2015

SAN DIEGO, May 15, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
May 14, 2015 08:00 ET | Source: Receptos, Inc.

Receptos to Present at UBS Global Healthcare Conference

SAN DIEGO, May 14, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
May 07, 2015 08:00 ET | Source: Receptos, Inc.

Receptos to Present at Bank of America Merrill Lynch 2015 Healthcare Conference

SAN DIEGO, May 7, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
May 05, 2015 16:01 ET | Source: Receptos, Inc.

Receptos Provides Business Update and Reports First Quarter 2015 Financial Results

- Positive Phase 2 induction and maintenance results for TOUCHSTONE trial of ozanimod (formerly RPC1063) in Ulcerative Colitis (UC) support broad development program in UC, Crohn's Disease - -...
April 29, 2015 08:00 ET | Source: Receptos, Inc.

Receptos to Hold First Quarter 2015 Results Conference Call

SAN DIEGO, April 29, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will...
April 16, 2015 08:00 ET | Source: Receptos, Inc.

Receptos Reports Positive Results for the Maintenance Period of the Phase 2 TOUCHSTONE Trial of Ozanimod in Ulcerative Colitis

- Study met all efficacy endpoints with statistical significance for patients on 1 mg dose after 32 weeks of treatment - - Safety data are consistent with the favorable profile observed in prior...
April 01, 2015 08:00 ET | Source: Receptos, Inc.

Receptos Completes Enrollment of RADIANCE Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis

SUNBEAM Phase 3 Trial of Ozanimod in Relapsing Multiple Sclerosis Continues to Enroll According to Plan; Overall Phase 3 Program on Track to be Completed in 1H 2017 Receptos Well Capitalized to...
March 09, 2015 08:00 ET | Source: Receptos, Inc.

Receptos to Present at Barclays Global Healthcare Conference

SAN DIEGO, March 9, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
March 03, 2015 16:01 ET | Source: Receptos, Inc.

Receptos Provides Development Updates and Reports Fourth Quarter and Year End 2014 Financial Results

- Positive Phase 2 induction results for TOUCHSTONE trial of ozanimod (formerly RPC1063) in Ulcerative Colitis (UC) support initiation of broad development program in UC, Crohn's Disease - - Both...